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Aim: Gold nanoparticles have attracted significant interest in cancer diagnosis 
and treatment. Herein, we evaluated the theranostic potential of dithiolated 
diethylenetriamine pentaacetic acid (DTDTPA) conjugated AuNPs (Au@DTDTPA) 
for CT-contrast enhancement and radiosensitization in prostate cancer. Materials & 
methods: In vitro assays determined Au@DTDTPA uptake, cytotoxicity, radiosensitizing 
potential and DNA damage profiles. Human PC3 xenograft tumor models were used 
to determine CT enhancement and radiation modulating effects in vivo. Results: Cells 
exposed to nanoparticles and radiation observed significant additional reduction in 
survival compared with radiation only. Au@DTDTPA produced a CT enhancement 
of 10% and a significant extension in tumor growth delay from 16.9 days to 38.3 
compared with radiation only. Conclusion: This study demonstrates the potential 
of Au@DTDTPA to enhance CT-image contrast and simultaneously increases the 
radiosensitivity of prostate tumors.
First draft submitted: 19 February 2016; Accepted for publication: 5 May 2016; 
Published online: 27 July 2016
Keywords:  cancer • CT enhancement • DTDTPA • gold nanoparticles • prostate • radiation 
enhancement • SARRP
The unique properties of nanoparticles offer 
significant potential for the development of 
novel materials that provide innovative solu-
tions to both diagnostic and therapeutic chal-
lenges in medicine. Nanoscale theranostic 
approaches, integrating properties for cancer 
diagnosis and therapy, could offer significant 
advantages over separately administered diag-
nostic and therapeutic agents [1–3]. Where a 
single nanoparticle formulation may be lim-
ited to targeting a specific biological process, 
the abilities of multifunctional nanoparticles 
to simultaneously enhance imaging and ther-
apy could offer much improvement beyond 
current standard of care.
Gold nanoparticles (AuNPs) are among the 
most widely studied nanoagents, largely due to 
a variety of unique physical, chemical and opti-
cal properties. Notable features include ease 
of synthesis, relative biocompatibility, tune-
able optical properties based on the surface 
plasmon resonance (SPR; associated with size 
and surface geometry of the nanoparticle) and 
importantly the ability to manipulate down-
stream applications through the conjugation 
of secondary functional groups [4–11]. Exploit-
ing the electron dense nature of gold has led to 
the evaluation of AuNPs as contrast agents for 
a wide range of imaging modalities including 
optical, x-ray, computed tomography (CT), 
Raman spectroscopy, multiphoton  microscopy 
and photo-acoustic imaging [12–16].
In addition, AuNPs have been well docu-
mented as radiosensitizers in in vitro and in vivo 
models (reviewed in Butterworth et al.) [17,18], 
with effects attributed to a combination of 
physical (secondary electron liberation), 
chemical (radiolysis mediated effects) and bio-
logical (DNA damage/reactive oxygen species 
[ROS] scavenging responses) effects [18–20].
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CT imaging is frequently used to generate tomo-
graphic images of soft tissue and vasculature, allowing 
high levels of precision in differentiating tissue types, 
and aiding tumor diagnosis and treatment planning. 
AuNPs provide excellent contrast, owing to their 
electron dense nature and SPR. The superior absorp-
tion coefficient of gold relative to soft tissue, bone and 
tumor, generates up to three-times more contrast per 
unit weight compared with iodine [12]. Reuveni et al. 
functionalized AuNPs with anti-EGFR, which were 
injected into mice with human squamous cell carci-
noma head and neck cancer, and subsequently imaged 
with CT. Untargeted and EGFR conjugated AuNPs sig-
nificant enhanced tumor contrast by 2.3- and 5.6-fold, 
respectively, over control levels [21].
Rationally, AuNPs should enhance passive tumor 
specific accumulation due to the vascular pathophysiol-
ogy, referred to as the enhanced permeability and reten-
tion effect (EPR), first described by Maeda et al. [22]. 
To ensure colloidal stability in physiological condi-
tions, diethylenetriaminepentacetic acid (DTPA) was 
grafted onto 2.4 nm AuNPs through two thiol moi-
eties, termed dithiolated diethylenetriamine pentaace-
tic acid (DTDTPA), with the AuNP conjugate referred 
to as Au@DTDTPA [23]. In previous biodistribution 
studies these nanoparticles were shown to passively 
accumulate within tumor tissue, and are rapidly cleared 
without reticuloendothelial retention by renal excre-
tion [24]. Furthermore, Au@DTDTPA conjugated with 
gadolinium (Au@DTDTPA-Gd
50
) demonstrated effi-
cient renal clearance while simultaneously generating 
enhanced CT and MRI capability [24]. In a separate 
study, osteosarcoma bearing animals were treated with 
microbeam radiation therapy, improving median sur-
vival time from 42.5 days to 61 following the inclusion 
of Au@DTDTPA. At this point the study was termi-
nated, with an apparent disappearance of the tumor in 
six of the seven animals, demonstrating a major survival 
improvement under microbeam radiation [25].
In the current study, we aimed to evaluate the ther-
anostic potential of Au@DTDTPA nanoparticles in a 
series of cell-based assays and using a preclinical model 
of prostate cancer radiotherapy. To date, radiosensitiz-
ing studies of AuNPs in prostate cancer remain lim-
ited, with only one study demonstrating in vivo effi-
cacy using goserelin functionalized gold nanorods [26]. 
In this study we report, for the first time, preclinical 
rationale for the use of Au@DTDTPA as an efficient 
theranostic agent in prostate cancer.
Materials & methods
Synthesis of Au@DTDTPA nanoparticles
Au@DTDTPA nanoparticles were synthesized accord-
ing to the protocol of Brust et al. [27] and as previously 
described by Debouttiere et al. [23]. HAuCl
4
•3H
2
O was 
reduced with NaBH
4
 in the presence of DTDTPA, a 
thiol stabilizer which adsorbs onto the surface of the 
growing particles and ensures control of size and stabil-
ity of the colloid. Au@DTDTPA nanoparticles were 
prepared at a concentration of 10 g/l in a deionized 
water solution and subsequent dilution in cell culture 
media was performed for storage.
Physical characterization of Au@DTDTPA 
nanoparticles
The physical properties of Au@DTDTPA nanoparti-
cles were characterized by transmission electron micros-
copy [24] and dynamic light scattering. High-resolution 
transmission electron microscopy (HRTEM) was car-
ried out using a JEOL 2010 microscope operating at 
200 kV. The hydrodynamic size, charge and polydis-
persity index (PDI) of Au@DTDTPA as synthesized 
and following incubation in medium containing 10% 
FBS and was measured using dynamic light scattering 
with a Malvern Zetasizer ZS (Malvern Instruments, 
Malvern, UK).
Cell culture
The human prostate cancer cell lines, PC3 and 
DU145, and the immortalized normal prostate epi-
thelial cell line, PNT2-C2, were cultured in Roswell 
Park Memorial Institute medium (RPMI-1640) sup-
plemented with 10% fetal calf serum (FCS) and 1% 
penicillin-streptomycin. PC3 and DU145 cells were 
purchased from the American Type Culture Collec-
tion []. PNT2-C2 were kindly donated by Prof Nor-
man Maitland at the University of York [28]. Cells were 
maintained in a humidified atmosphere at 37°C with 
5% CO
2
 and subcultured every 3–4 days to maintain 
exponential growth.
Atomic absorption spectroscopy
Cells (2.5 × 105) were seeded, allowed to adhere for 
24 h and incubated with media containing 100, 250 
and 500 μg/ml Au@DTDTPA for a further 24 h. 
AuNPs were then aspirated and cells washed twice 
with PBS to remove surface bound particles, trypsin-
ized and centrifuged at 8000 rcf for 5 min. The 
supernatant was removed and the pellet resuspended 
in 1 ml PBS. A 50 μl aliquot of the cell suspension 
was removed and counted to determine the cell num-
ber. The remaining sample was dissolved in 1 ml of 
aqua regia (1 part 70% nitric acid, to 3 parts 37% 
hydrochloric acid). Each sample was made up to 5 ml 
with 18.2 MΩ·cm water and the gold content deter-
mined by atomic absorption spectroscopy (AAS) with 
flame atomizer to measure absolute  quantification of 
elemental gold.
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In vitro cytotoxicity
The cytotoxicity of Au@DTDTPA nanoparticles was 
measured using the fluorescent Alamar blue assay. 
1.5 × 104 cells were plated in a 96-well plate, allowed 
to adhere for 24 h then supplemented with 100, 250 
and 500 μg/ml Au@DTDTPA for a further 24 h. 
Excess Au@DTDTPA were removed, the cells washed 
twice with PBS and cells incubated in media contain-
ing 10% Alamar blue reagent for 4 h. Media was then 
transferred to a 96-well black out plate and read on 
a fluorescent plate reader at 570 nm excitation and 
585 nm emission.
Clonogenic assay & in vitro irradiation 
procedure
A total of 2.5 × 105 exponentially growing cells were 
plated in 35 mm2 dishes and allowed to adhere over-
night before incubation with Au@DTDTPA nanopar-
ticles in complete culture medium for 24 h. Excess 
nanoparticles were removed, cells washed twice with 
PBS and incubated in complete media prior to irra-
diation. In vitro experiments were performed with 
225 kVp x-rays generated using a X-Rad 225 genera-
tor (Precision X-ray Inc., CT, USA) with a 2 mm cop-
per filter. All quoted doses are the absorbed dose in 
water 50 cm from the radiation source at a dose rate of 
0.591 Gy/min. Following irradiation, cells were tryp-
sinized, diluted 1:1 in fresh medium and vortexed to 
ensure a homogenous solution before being counted 
and reseeded at low densities for clonogenic assay as 
described by Puck and Marcus [29]. After 14 days, 
colonies were fixed with 0.4% crystal violet in 70% 
methanol and counted applying a 50-cell exclusion cri-
terion. Surviving fraction was calculated as previously 
reported [30].
DNA damage analysis by immunofluorescence 
microscopy
Cells were plated at a density of 2 × 104 cells onto 
4 chamber microscope slides and allowed to adhere 
overnight. A solution of 250 μg/ml of AuNP was added 
to the cells and incubated for 24 h prior to irradiation 
with 1 Gy. Subsequently, cells were fixed using a 50% 
MeOH/50% acetone solution at 1 or 24 h post treat-
ment to determine if Au@DTDTPA enhanced dou-
ble strand break damage or prolonged DNA damage 
repair. Cells were rinsed three-times with PBS (Sigma, 
UK) and incubated with a blocking buffer of 0.2% 
milk (Sigma, UK), 5% fetal bovine serum (Gibco, Life 
Technologies, UK) and 0.1% Triton X-100 in PBS for 
1 h at room temperature. Slides were then incubated 
with 53BP1 antibody (Novus Biologicals, CO, USA) at 
a dilution of 1:5000 in blocking buffer for 1 h at room 
temperature. They were then rinsed three-times with 
PBS before being incubated with Alexafluor 488 Goat 
anti Rabbit secondary antibody (Invitrogen Molecular 
Probes, Oregon, USA) at a dilution of 1:1000 in block-
ing buffer and costained with ProLong® Gold Anti-
fade mounting medium with DAPI. DNA damage was 
quantified by immunofluorescence detection of 53BP1 
and nuclear foci were manually scored for 50 cells per 
slide using a Zeiss Axiovert 200 M microscope (Carl 
Zeiss MicroImaging, LLC, USA).
Au@DTDTPA induced ROS yields measured by 
DCFDA
A total of 1.5 × 104 cells were plated and left to adhere 
for 24 h before being washed twice in PBS and supple-
mented with fresh medium containing 5 μM DCFDA 
(Abcam, UK) for 40 min. Media containing the dye 
was removed and replaced with fresh media containing 
250 μg/ml AuNPs for varying time intervals. Samples 
were read on a fluorescent plate reader at excitation/
emission 495/529 nm. A total of 5 μM tert-butyl 
hydrogen peroxide was used as a positive control to 
demonstrate induction of ROS.
Cone beam CT imaging & in vivo radiation 
procedures using the small animal radiotherapy 
research platform
Cone beam CT (CBCT) images of a phantom loaded 
with different concentrations of Au@DTDTPA 
nanoparticles were obtained at 50 kV and 0.6 mA 
using a small animal radiotherapy research platform 
(SARRP; XStrahl, Life Sciences). Analysis of CBCT 
datasets was performed by determining the CT num-
bers from the nanoparticle samples relative to water 
for defined regions of interest. A calibration curve for 
CT number relative to water as a function of AuNP 
concentration was obtained and used to correlate the 
in-phantom x-ray absorbance measurements with the 
pretreatment CBCT images. CBCT phantom experi-
ments allowed the determination of intratumoral 
AuNP concentration by comparing the CT number 
ratio relative to tissue. For the experiments presented, 
CBCT data at 10 min post injection were analyzed and 
compared against in-phantom measurements.
Prior to CBCT-guided irradiation, mice were anes-
thetized by intraperitoneal injection of xylazine/ket-
amine. Au@DTDTPA nanoparticles were delivered 
by intratumoral injection into tumor bearing mice 
at a concentration of 8 mg/kg equating to 160 μg of 
Au@DTDTPA per 20 g animal. Treatment planning 
was performed in MuriPlan (Xstrahl Life Sciences) to 
achieve uniform dose distributions across the tumor 
target by delivering two parallel opposed 10 × 10 mm 
beams and avoiding critical structures. Therapeutic 
radiation doses were delivered 10–15 min after Au@
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DTDTPA injection and CT scan. Animals were placed 
in a recovery incubator after the treatment.
In vivo tumor growth delay model
Six- to 8-week-old male Fox Chase SCID (severe com-
bined immunodeficient) mice (Charles River Labora-
tories, Oxford, UK) were used as a xenograft model 
for PC-3 cells. A total of 1.5 × 106 cells in 80 μl of 
phosphate-buffered saline (PBS) were implanted intra-
dermally on to the flank of animals under inhalant 
anesthesia. Tumors were allowed to grow to 100 mm3 
before being randomly assigned to one of four experi-
mental groups; Au@DTDTPA + IR, 4 Gy IR only, 
Au@DTDTPA only (8 mg/kg) and untreated con-
trols. Au@DTDTPA was administered as described 
above. Upon recruitment to the study animal weights 
and tumor volume were measured three-times weekly. 
Tumor volume was determined in three orthogonal 
dimensions. Experimental endpoints for individual 
animals were defined by tumor volume exceeding 
400 mm3 or animals losing in excess of 10% of their 
body weight at the start of the experiment. Animals 
received food and water ad libitum. All experimental 
procedures were carried out in accordance with United 
Kingdom Home office approved protocols for in vivo 
experimentation.
Statistical analysis
All results presented are the mean of at least three inde-
pendent experiments ± standard error mean (SEM). 
Plots were obtained using Prism version 5.01, with sta-
tistically significant differences calculated using a two-
tailed unpaired t-test with a p-value of ≤ 0.05 considered 
significant. Statistical significance for in vivo Kaplan–
Meier survival curves was calculated using the Mantel–
Cox test with p ≤ 0.05 considered significant. Figure 
annotations of statistical significance are represented as 
follows: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
Results
Physical properties of Au@DTDTPA 
nanoparticles & determination of intracellular 
concentrations
The physical properties of Au@DTDTPA are sum-
marized in Figure 1A–C. DTDTPA molecules were 
conjugated to the surface of the core AuNP via two 
thiol groups leading to the formation of a stable multi-
layered ligand shell. The mean core AuNP size deter-
mined by TEM was shown to be 2.4 ± 0.5 nm, with 
DTDTPA conjugation increasing the hydrodynamic 
size to 5.37 ± 0.17 nm. The synthesized particles had 
an overall negative surface charge of -29.6 mV at pH 
7.4, exhibiting a highly homogenous distribution in 
solution with a PDI of 0.3 ± 0.021. Nonspecific protein 
absorption results in the formation of a protein corona 
that can negatively impact biological activity [31]. To 
establish the stability of Au@DTDTPA in serum con-
taining medium nanoparticles were incubated in com-
plete medium containing 10% FBS. Particle size was 
determined at multiple time points over a 24 h period, 
with no significant change in hydrodynamic size or 
PDI indicating a high degree of stability in serum 
 containing medium.
Intracellular concentrations of Au were calculated 
from a standard curve (R2 = 0.992) of anticipated 
nanoparticle concentrations plotted against measured 
values using AAS (Figure 2A). Figure 2B–D shows the 
absolute quantification of intracellular Au@DTDTPA 
content determined by AAS in cells incubated with 
increasing concentrations of Au@DTDTPA particles 
for 24 h. Two wash steps were used to ensure that only 
intracellular gold was quantified.
Cell line dependent variations were observed across 
all nanoparticle concentrations with a dose-depen-
dent effect observed in PC3 and PNT2-C2 cells 
(Figure 2B & D). PC3 cells exhibit minimal uptake at 
100 μg/ml, achieving mean intracellular Au concen-
trations of 0.29 pg/cell, while DU145 and PNT2-C2 
cells show a 2.23- and 3.79-fold increase, highlight-
ing a cell type dependent variation in endocytosis. 
Increasing the Au@DTDTPA concentration from 100 
to 250 μg/ml significantly increased the intracellular 
nanoparticle concentration by 5.4-, 1.17- and 2.05-
fold in PC3, DU145 and PNT2-C2 cells respectively 
following a 24 h exposure. Furthermore, doubling 
Au@DTDTPA concentrations to 500 μg/ml resulted 
in maximal intracellular concentrations of 3.65, 1.8 
and 3.46 pg/cell in PC3, DU145 and PNT2-C2 cells, 
respectively, representing a close to linear uptake 
in PC3 and DU145 cells at higher concentrations. 
Au@DTDTPA concentrations exceeding 500 μg/ml 
were not investigated due to  evidence of cytotoxicity at 
higher concentrations.
Au@DTDTPA cytotoxicity
The Alamar blue assay was used to test the short-
term cytotoxicity of Au@DTDTPA over a 28 h time 
period following initial exposure to Au@DTDTPA 
(24 h Au@DTDTPA and 4 h Alamar blue exposure). 
Exposure concentrations were the same as those used 
to determine intracellular uptake. Figure 3 represents 
cytotoxicity normalized to the mean viability of the 
control cells which were not exposed to AuNPs. Treat-
ment with Au@DTDTPA negatively impacted short-
term viability, resulting in a mean reduction by 21.6% 
± 1.59% in all cells treated with nanoparticles up to 
concentrations of 250 μg/ml. Increasing the exposure 
concentration of Au@DTDTPA to 500 μg/ml resulted 
www.futuremedicine.com 2039
Figure 1. Physical characterization and stability of Au@DTDTPA nanoparticles. (A) High resolution transmission 
electron micrograph of Au@DTDTPA nanoparticles. (B) Dynamic light scattering analysis of Au@DTDTPA 
hydrodynamic size, charge and polydispersity index. (C) Au@DTDTPA hydrodynamic size following incubation in 
complete RPMI medium containing 10% FBS. Error bars represent SEM.
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in significant (p < 0.01) cytotoxicity reducing viability 
by up to 45.5% in DU145 cells, with equivalent high 
toxicity levels observed in both of the other cell lines.
In vitro radiosensitization & DNA damage 
measurements
Long-term cytotoxicity was quantified by the gold 
standard colony formation assay using an intermediate 
exposure concentration of Au@DTDTPA at 250 μg/ml 
(Figure 4A). No significant reduction in clonogenicity 
was observed in any cell line over 12 days indicating 
that any increased reduction in surviving fraction when 
used in combination with radiation was attributable to 
a synergistic radiosensitizing effect and independent 
of any short-term toxicity measured using the Alamar 
Blue viability assay. Radiosensitization was determined 
following pretreatment of cells with various concentra-
tions of Au@DTDTPA over 24 h then irradiating at a 
dose of 4 Gy. Figure 4B–D shows the survival fraction 
of Au@DTDTPA doped cells relative to IR alone. Pre-
treatment with 250 μg/ml of Au@DTDTPA resulted 
in an additional 84, 68 and 87% reduction in colony 
formation relative to 4 Gy in PC3 DU145 and PNT2-
C2 cells, respectively. Further decreases in cell sur-
vival were observed when combining 500 μg/ml Au@
DTDTPA with a 4 Gy radiation dose, however, this 
concentration of nanoparticles was also associated with 
significant cytotoxicity (Figure 3). Consequently, all 
subsequent in vitro experiments were performed using 
a nanoparticle concentration of 250 μg/ml.
DNA damage was quantified using the 53BP1 assay 
following a 24 h incubation with Au@DTDTPA 
prior to irradiation. Figure 5A–C shows the 53BP1 foci 
(a surrogate marker for DNA double strand breaks 
[DSB]) 1 and 24 h post irradiation, in the presence 
and absence of AuNPs. No significant difference in the 
level of DNA DSB damage were observed in the pres-
ence of Au@DTDTPA 1 h post radiation, indicating 
that damage induction is dominated by the effects of 
ionizing radiation (Figure 5Ai–Ci). Levels of residual/
unrepaired DSB were also quantified 24 h post radia-
tion treatment where PC3 cells were shown to have 
1.7-fold higher level of residual damage in the pres-
ence of Au@DTDTPA compared with cells receiving 
radiation only. These findings suggest that AuNPs 
have a negative impact DNA damage repair causing 
2040 Nanomedicine (Lond.) (2016) 11(16)
Figure 2. (A) Standard curve of Au@DTDTPA nanoparticles to determine intracellular Au concentrations using 
atomic absorption spectroscopy. (B–D) Intracellular concentration of Au determined by AAS following a 24 h 
incubation with increasing concentrations (100, 250 and 500 μg/ml) of Au@DTDTPA in PC3, DU145 and PNT2-C2 
cells, respectively.
Figure 3. (A–C) PC3, DU145 and PNT2-C2 cytotoxicity data determined by fluorescent Alamar blue assay, following a 24 h incubation 
with Au@DTDTPA. Survival fraction was determined relative to the untreated control, while error bars represent SEM.
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more persistent damage that may be due to more com-
plex damage lesions in the nuclear DNA. A nonsig-
nificant effect was observed in PNT2-C2 cells, the 
opposite effect was seen in DU145 cells, significantly 
(p < 0.01) stimulating the damage response. The con-
tribution of nanoparticle induced ROS was also deter-
mined using DCFDA, a nonfluorescent compound 
that become fluorescent following oxidation by non-
specific ROS (Figure 5A.II–C.II). In all three cell lines, 
Au@DTDTPA resulted in a small time dependent 
increase in ROS yields, although not to a statistically 
level when compared against the untreated control 
www.futuremedicine.com 2041
Figure 4. (A) Relative colony forming potential of PC3, DU145 and PNT2-C2 cells exposed to 250 μg/ml Au@
DTDTPA. Cells were exposed to Au@DTDTPA for 24 h prior to receiving a 4 Gy dose of 225 kVp x-rays. (B–D) PC3, 
DU145 and PNT2-C2 radiosensitizing efficacy was determined by changes in colony forming efficacy relative to 
cells receiving radiation only.
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cells. As a consequence the variable cell line dependent 
response, particularly with respect to DNA damage, 
and due to the significant in vitro radiosensitization, 
PC3 cells were selected to establish both the diagnostic 
and  therapeutic potential of Au@DTDTPA in vivo.
Enhancement of CBCT imaging
Prior to in vivo imaging studies, x-ray absorption 
experiments were carried out with nanoparticle solu-
tions at various concentrations of Au@DTDTPA 
nanoparticles. CBCT images of phantoms containing 
Au@DTDTPA at various gold concentrations (from 
0.42 to 8.4 mg/ml) were obtained at 50 kV, 0.6 mA 
using the on-board CBCT imaging capabilities of the 
SARRP (Figure 6A). Au@DTDTPA nanoparticles 
show obvious contrast enhancement relative to water 
which increases linearly to plateau a concentrations 
above 4.2 mg/ml (Figure 6B).
In vivo images were then analyzed and the CT num-
bers relative to tissue were compared for the control 
group and AuNP injected group. Assuming the 10 min 
time-lapse post injection was suboptimal for tumor 
uptake, negative contrast was observed within the 
tumor interstitium. This setup was then used to study 
the differential contrast in the tumor or in AuNP accu-
mulation around the tumor. Significant correlation 
was found between subcutaneous AuNP accumulation 
CT ratio and the in-phantom output for the 8.4 mg/
ml (Figure 6C). As anticipated, the tumor to tissue CT 
ratio showed no increase indicating minimal uptake in 
the tumor for the stated time point.
Xenograft tumor growth delay model
Fox Chase SCID mice implanted with intradermal 
PC3 tumors were weighed (an indicator of animal 
health) and tumor volume recorded three times weekly 
2042 Nanomedicine (Lond.) (2016) 11(16)
Figure 5. DNA damage and reactive oxygen species yields following Au@DTDTPA treatment. DNA damage 
measurements were determined by immuno-fluorescent staining of 53BP1 following fixation 1 and 24 h post 
IR treatment. PC3 (5Ai) DU145 (5Bi) and PNT2-C2 (5Ci) cells were treated in the absence and presence of Au@
DTDTPA. Au@DTDTPA (250 μg/ml) induced reactive oxygen species was determined using DCFDA in PC3 (5Aii), 
DU145 (5Bii) and PNT2-C2 (5Cii) cells.
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(Figure 7). Established tumors were defined as reach-
ing 100 mm3 at which point animals were randomly 
assigned to one of four treatment groups. Mean animal 
weights per treatment group show only minor fluctua-
tions over the course of the study, while all animals 
tolerated nanoparticle treatments well with no appar-
ent signs of morbidity based on body condition scoring 
(Figure 7A).
Untreated control animals developed highly pro-
liferative tumors, exhibiting a mean increase of 15% 
tumor volume per day. As a consequence all untreated 
control animals exceeded the experimental endpoint of 
www.futuremedicine.com 2043
Figure 6. Phantom and in vivo cone beam CT imaging of Au@DTDTPA nanoparticles. (A) CBCT images for 
nanoparticles concentrations of 8.4 (1), 4.2 (2), 0.84 (3), 0.42 (4) mg/ml, water (5) and air (6). (B) Calibration 
curve of CBCT ratio (AuNP:water) for different nanoparticle concentrations. (C) CBCT enhancement values. 
(D) representative CBCT images (i) before, and (ii) after intratumoral injection with AuNPs.
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400 mm3 within 10 days of recruitment. Despite Au@
DTDTPA-mediated cytotoxicity observed in vitro, 
treatment alone at 8 mg/kg had a minimal impact on 
tumor growth extending survival by 2.6 ± 1.4 days. The 
impact of a single fraction of 4 Gy x-ray significantly (p 
= 0.008 compared with untreated controls) impaired 
tumor growth resulting in tumor stasis for up to 16 days 
post treatment, after which progression was observed at 
an equivalent rate to that seen in Au@DTDTPA-treated 
animals. Consequently, radiation only treated animals 
took an additional 16.9 ± 4.4 days to reach 300 mm3 
compared with control animals (Figure 7C). However, in 
agreement with the significant radiosensitizing effects 
observed in vitro, the combination of Au@DTDTPA 
and IR significantly (p = 0.007) attenuated tumor 
growth over radiation alone, taking 38.34 ± 1.9 days for 
tumors to triple in volume, an extension in tumor growth 
delay of over 11 days. Both IR only and Au@DTDTPA 
+ IR treated animals produced similar tumor growth 
characteristics, with a prolonged delay without tumor 
regression post treatment that was  eventually overcome 
 resulting in rapidly growing tumors.
Kaplan–Meier survival curves (Figure 7D) demon-
strate a marked improvement in survival fraction for 
Au@DTDTPA + IR, both in terms of the first death 
(32 days compared with 18 days with IR alone) and 
last (42 vs 38 days). This is further reflected through 
median survival times of 38 days for Au@DTDTPA 
+ IR compared with 29 days with IR alone, demon-
strating a 31% increase in median survival with the 
combined treatment.
Discussion
The synthesis procedure for Au@DTDTPA nanopar-
ticles yields a homogenous population with a hydro-
dynamic size of 5.37 nm and an overall negative sur-
2044 Nanomedicine (Lond.) (2016) 11(16)
Figure 7. Xenograft tumor growth delay model in male Fox Chase severe combined immunodeficient mice 
implanted with PC3 prostate cancer cells. Animals were divided into experimental groups untreated, Au only 
(a single intratumoral injection at a concentration of 5 mg/kg Au@DTDTPA), 4 Gy and Au + 4 Gy. IR was delivered 
as 4 Gy dose in two parallel opposed beams, guided by CT imaging on the small animal radiation research 
platform (SARRP). (A) Mean animal weight per treatment group indicating no weight loss. (B) Mean tumor 
growth characteristics of the four treatment groups. Tumors were permitted to grow until the predetermined 
experimental end point of 400 mm3. (C) Treatment efficacy defined by the delay in time taken for tumors 
to increase three-fold from the point of recruitment to the study. Statistical analysis was performed using a 
two-tailed t-test. (D) Kaplan–Meier survival curves demonstrating individual animal survival characteristics. 
Experimental start point varies from tumor implantation (A) to a tumor volume of 100 mm3 (B & D).
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face charge (-29 mV). Incubation of nanoparticles in 
medium containing serum is a recognized methodol-
ogy for assessing the evolution of a nonspecific pro-
tein corona [32]. MS analysis of medium containing 
serum identified more than 10,500 individual proteins 
ranging in concentrations up to 0.07 g/ml [33]. Nano-
particles grafted with cationic surface groups generate 
positively charged particles that are designed to enhance 
electrostatic interactions with negatively charged cell 
membranes, thereby promoting nanoparticle internal-
ization. However, this strategy is potentially flawed as 
it results in nonspecific interactions with serum pro-
teins that coat the nanoparticle surface, influencing 
 biological activity and clearance [34].
The negative ζ potential of Au@DTDTPA provides 
dual protection through electrostatic repulsion by pre-
venting nanoparticle agglomeration and the absorp-
tion of serum proteins as evidenced by a stable hydro-
dynamic size and polydispersity index over a 24-h 
period. Furthermore, the potent stabilizing properties 
of DTDTPA further validates the findings of Debout-
tière et al. (2006) who reported excellent stability of 
a DTDTPA gadolinium:Au conjugate across a broad 
spectrum (pH 2–12) of pH solutions [23].
Conversely, electrostatic repulsion may negatively 
impact nanoparticle internalization. AAS was used 
to establish the concentration dependent effect of 
Au@DTDTPA on nanoparticle endocytosis. Nano-
particle uptake was observed in all cell lines reaching a 
maximum internal concentration of 3.65 pg/cell, indi-
cating that internalization occurred independent of sur-
face charge. While a positive charged nanoparticle may 
initially result in higher uptake, the benefit of DTDTPA 
conjugation ensures that following in vivo administra-
tion nanoparticles are protected from opsonization and 
reticulo-endothelial clearance [35].
www.futuremedicine.com 2045future science group
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Cytotoxicity is a significant issue associated with 
emerging nanoparticle theranostic agents. While con-
cerns exist with respect to gadolinium chelates used in 
MRI, AuNPs are generally considered to be biocompat-
ible [36,37]. However, in our initial cell viability assays, all 
concentrations of Au@DTDTPA negatively impacted 
cell survival by approximately 20%, while at the highest 
concentrations survival was reduced by up to 45%. As 
a consequence, subsequent experiments were performed 
using the intermediate exposure concentration of 250 μg/
ml. While this may appear as a limiting factor, it does not 
mirror the effects observed on long-term survival in vitro 
determined by clonogenic assay, nor were any adverse 
effects observed following in vivo administration.
In the context of clinical cancer treatments (cyto-
toxic chemotherapy or targeted agents) no agents are 
nontoxic and in some cases have significant toxicity 
indications. Taxane-based chemotherapies represent 
the first line of treatment for patients with metastatic 
prostate cancer [38]. Despite high-level sensitivity of 
prostate cancer cells (DU145) to docetaxel (IC
50
 8.7 
nM), it is associated with significant toxicity issues 
in the clinic particularly in patients with hematopoi-
etic abnormalities resulting in febrile neutropenia and 
acute hepatocellular toxicity [39].
To establish the radiosensitizing potential of Au@
DTDTPA, PC3, DU145 and PNT2-C2 cells were 
exposed to various doses of nanoparticles prior to irra-
diation with a single 4 Gy dose. In most cases nanopar-
ticle concentration plus radiation inversely correlated 
with survival, resulting in significant radiosensitizing 
effects (Figure 4). Importantly, these effects translated 
into highly significant PC3 tumor growth delay in ani-
mals treated with Au@DTDTPA, extending survival 
by 31% over animals receiving radiation only. The sig-
nificance of this finding is increased when considered 
alongside existing simulated and experimental datasets. 
Based on Monte Carlo simulations of AuNP radiosen-
sitization, intratumoral concentrations of almost 1% 
wt/wt (7 mg Au/g tumor) are required to achieve a 
twofold dose enhancement using 140 kVp x-rays [40]. 
Similarly, early in vivo experimental studies by Hain-
feld achieved substantial improvements in survival 
for animals treated with AuNPs in combination with 
radiation in both mammary carcinoma and glioblas-
toma tumor models [41,42]. However, translation of 
this preparation into a clinically relevant nanoparticle 
is hampered by high treatment concentrations >1.35 
mg/g body weight, which if used in the same manner 
for human subjects would equate to more than 100 g 
AuNP per patient for an 80 kg individual. In the cur-
rent study, PC3 xenograft tumors were directly injected 
with a single treatment containing approximately 160 
μg of Au prior to radiation treatment, representing 
clinically feasible concentrations of Au per treatment. 
Although, direct intratumoral injections have limited 
applicability in the metastatic context, our approach 
could hold significant potential for a specific cohort 
of prostate cancer patients with locally advanced dis-
ease that has progressed beyond the prostatic capsule 
with possible invasion into the pericapsular tissue and 
seminal vesicles. Approximately 30% of T3–T4 lymph 
node negative, metastasis negative prostate cancers 
ultimately fail treatment [43]. Intervention with radical 
radiotherapy in combination with effective radiosen-
sitizers such as Au@DTDTPA represents an alterna-
tive, viable solution to improving treatment outcome 
for these patients. The application of a potent radio-
sensitizer used in combination with a lower radiation 
treatment dose could significantly minimizing off-tar-
get toxicity to tissues such as the rectum and bladder. 
Additionally, enhanced CT-contrast afforded by the 
Au@DTDTPA (Figure 6) could be incorporated into 
cone beam-CT image-guided radiotherapy treatment 
plans to further minimize the risk of off-target damage.
Conclusion
Used in the appropriate clinical context, as described 
above, or optimized with specific targeting motifs to 
ensure efficient tumor specific accumulation, AuNPs 
hold significant potential as theranostic agents for radio-
therapy. In the current study, surface conjugation with 
DTDTPA provided stable protection against nanopar-
ticle agglomeration and protein absorption, while retain-
ing an acceptable endocytotic uptake to yield potent 
radiosensitization in both in vitro and in vivo models. 
Further optimization of nanoparticle dosing schedule 
with fractionated radiation protocols will help to  facilitate 
 transition from preclinical study to first in man trials.
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